Interestingly, the specific CatK inhibitor, balicatib, was reported to increase intact parathyroid hormone levels in clinical human trials for osteoporosis by 50% (discussed in [34]) corroborating the potential of CatK to degrade regulatory factors. Here, PTH is linked to osteoporosis.